Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis. ILCs have several functional similarities to T-cells and are important agents of our congenital immune system. The FAU researchers’ findings could form the basis for new approaches for treating rheumatoid arthritis. The findings have now been published in the renowned journal ‘Cell Reports’.
Rheumatoid arthritis is the most common form of inflammatory joint conditions. In contrast to osteoarthritis, where patients’ joints degenerate, the symptoms of arthritis such as overheating, swelling and redness, occur in flare-ups and are frequently caused by disturbances in the immune system. The disease mainly affects the fingers and toes, but also knees, shoulders and hip joints. Around one percent of the population suffer from the condition and women are three times more likely to suffer from it than men. Treatment usually focuses on easing pain and slowing down the progression of the disease as there is no cure for rheumatoid arthritis.
Rare immune cell regulates arthritis
Immunologists at FAU have now proven that ILC2, a rare form of lymphocyte, plays a key role in the development of rheumatoid arthritis. Although ILCs, so-called ‘innate lymphoid cells’, do not have the T cell and B cell receptors nor cell type markers that are otherwise typical for lymphocytes, they are pivotal in defending the human body from pathogens. They are often the ‘first aiders’ who alarm the immune system before the actual immunisation begins. ‘From earlier research, we know that ILC2 can initiate the suppression of chronic inflammation by producing the cell signal molecule IL-9’, says project manager Dr. Mario Zaiss from the Department of Medicine 3 – Rheumatology and Immunology at Universitätsklinikum Erlangen. ‘In our current study, we specifically examined the role of ILC2s in the early stage of rheumatoid arthritis’.
ILC2 only helps before the onset of the disease
Firstly, Zaiss and his colleagues were able to demonstrate that the number of ILC2 in the peripheral blood and in the joints of patients with rheumatoid arthritis is significantly higher than in healthy people. Laboratory tests confirmed the regulatory function of ILC2. When the researchers reduced the number of these immune cells genetically, this exacerbated the progression of the disease later on, while increasing the number of ILC2 during therapy significantly reduced the arthritis. The researchers, however, cannot hold out any hope that they will be able to cure patients who already have inflammatory arthritis through targeted enrichment of ILC2. ‘There is no doubt that ILC2 has a regulatory effect during the early stage of arthritis,’ explains Mario Zaiss. ‘However, any treatment must start before the onset of the disease – transferring ILC2 later on does not improve symptoms.’
Further research is set to find safe methods of increasing the number of ILC2 in the body in a targeted manner. Researchers must also find new and reliable methods of detecting signs of arthritis before the onset of the disease as this is the only time when these rare lymphocytes can be used as a treatment.
Contact for scientific information:
Dr. Mario Zaiss
Phone: +49 9131 8543212
Doi: 10.1016/j.celrep.2018.06.005 ‘Group 2 Innate Lymphoid Cells Attenuate Inflammatory Arthritis and Protect from Bone Destruction in Mice’ in Cell Reports.